Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.
Variant Bio has raised $105.0M in total funding. The most recent round was Series B. The last funding was announced in November 2021.
Variant Bio's investors include General Catalyst, Lux Capital, Casdin Capital, Alexandria Venture Investments, SoftBank Vision Fund.
Variant Bio is headquartered in Seattle, United States.
Variant Bio is leveraging the power of human genetic diversity to discover new therapeutics.
Variant Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Variant Bio — Funding & Investors." VCBacked, November 9, 2021, https://www.vcbacked.co/company/variant-bio. Accessed August 15, 2026.
VCBacked. (2021). Variant Bio — Funding & Investors. Retrieved August 15, 2026, from https://www.vcbacked.co/company/variant-bio
{{cite web |title=Variant Bio — Funding & Investors |url=https://www.vcbacked.co/company/variant-bio |website=VCBacked |access-date=August 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated